<DOC>
	<DOCNO>NCT01933334</DOCNO>
	<brief_summary>PSSc-001 ( LOTUSS ) This study Phase 2 , multinational , open-label , randomize , parallel-group , safety tolerability study pirfenidone participant systemic sclerosis−related interstitial lung disease ( SSc-ILD ) .</brief_summary>
	<brief_title>Safety Tolerability Pirfenidone Participants With Systemic Sclerosis−Related Interstitial Lung Disease ( SSc-ILD ) ( LOTUSS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>1 . Diagnosis systemic sclerosis−related ( SSc ) confirm American College Rheumatology classification criterion systemic sclerosis ( Masi 1980 ) ; duration diagnosis le ( &lt; ) 7 year 2 . Diagnosis SScILD base highresolution compute tomography ( HRCT ) scan 3 . Screening forced vital capacity ( FVC ) great equal ( &gt; = ) 50 percent ( % ) predict value , screen carbon monoxide diffuse capacity ( DLCO ) &gt; =40 % predict value 4 . At study entry , participant either take SScILD medication take cyclophosphamide mycophenolate 1 . Clinically significant pulmonary hypertension 2 . Known underlying liver disease 3 . Clinical evidence significant aspiration uncontrolled gastroesophageal reflux 4 . History clinically significant asthma chronic obstructive pulmonary disease 5 . Active infection 6 . Diagnosis another connective tissue disorder 7 . Evidence malignancy likely result significant disability require significant medical surgical intervention 8 . History unstable deteriorate cardiac pulmonary disease ( SScILD ) 9 . Pregnancy lactation 10 . Creatinine clearance &lt; 40 milliliter per minute ( mL/min ) 11 . Prior use pirfenidone 12 . Unsuitable enrollment unlikely comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>pirfenidone</keyword>
	<keyword>SSc-ILD</keyword>
	<keyword>scleroderma</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>interstitial lung disease</keyword>
</DOC>